


Screening and Treatment (cetuximab + irinotecan/FA/5-FU)	Follow-up
---	-----------



SD, stable disease; PD, disease progression; EOS, end of study visit

\* Patients benefiting from combination therapy, but with unacceptable secondary intolerance to irinotecan and/or 5-FU/FA, could receive single-agent cetuximab until unacceptable toxicity or PD.